Information Provided By:
Fly News Breaks for August 11, 2015
CLDX
Aug 11, 2015 | 09:24 EDT
After Celldex said that it would delay filing for approval of its Rintega drug, Roth Capital says that the delay will have only a "modest" impact on the company's valuation, while the company's fundamentals remain upbeat, The firm trimmed its price target on the name to $39 from $43 but keeps a Buy rating.
News For CLDX From the Last 2 Days
There are no results for your query CLDX